FGFR2 and intrahepatic cholangiocarcinoma: Pemigatinib was the first FGFR inhibitor approved for previously treated FGFR2 fusion-positive intrahepatic cholangiocarcinoma, based on the FIGHT-202 trial, which showed an ORR of 35.5% [181].